Ketorolac indications

Ketorolac-oral, indicated for continuation 5-6 10 q 4-6 h (maximum of 5 days, 40... 

KETOROLAC TROMETHAMINE The combined duration of ketorolac IV/IM and oral is not to exceed 5 days. Oral use is only indicated as continuation therapy to IV/IM. 

Oral- Indicated only as continuation therapy to ketorolac IV/IM. 

Ketorolac tromethamine Ketorolac is indicated for the short-term (up to 5 days) management of moderately severe acute pain that requires analgesia at the opioid level. It is not indicated for minor or chronic painful conditions. Increasing the dose beyond the label recommendations will not provide better efficacy but will result in increasing risk of developing serious adverse events. 

Pharmacokinetic data indicate that ketorolac penetrates the cornea after topical ocular administration and reaches concentrations that reduce prostaglandin E levels in the aqueous humor. Plasma levels of ketorolac after topical ocular application are usually below detectable limits compared with oral administration. Ketorolac does not affect lOP, pupillary response, or visual acuity. 

If topical anesthetic abuse is suspected, discontinuation is critical. A broad-spectrum topical antibiotic such as 0.5% moxifloxacin three times daily is used to protect the disrupted corneal epithelium from secondary infection as the tissue heals. Topical NSAIDs, such as 0.1% diclofenac sodium solution or 0.5% ketorolac solution, and a therapeutic soft contact lens help to reduce pain. Cycloplegic and topical steroids are indicated if an anterior chamber reaction is present.Toxic keratitis can heal without permanent vision loss within days after discontinuing the use of the anesthetic but may result in permanent scarring, vascularization, and visual loss. Surgical treatment, such as a penetrating keratoplasty, may be necessary. 

Ketorolac (oral) (indicated for continuation In some patients, initial oral dose 20 40... 

Ketorolac (Toradol) The only nonsteroidal anti-inflammatory which is administered intramuscularly for pain relief. Initial clinical trials indicate that it is equal to narcotic analgesics for controlling postoperative pain. 

S-Fenoprofen concentrations greatly exceed those of the R enantiomer as a result of extensive chiral inversion [248]. An earlier report in a single subject indicated that the plasma concentrations of ketorolac enantiomers were nonstereoselective [251], but it was recognized later that a derivatiza-tion step in the assay [252] caused racemization of the enantiomers [253]. Assays using chiral columns have shown that plasma concentrations of inactive R-ketorolac are significantly higher than antipode [250,253]. This is consistent with a higher free fraction of S-ketorolac in plasma than that of the antipode (Table 3). 

Ketorolac is indicated for the short-term management of moderately severe acute pain. The primary setting for ketorolac is in post-operative patients that require opioid level analgesia. Duration of therapy should not exceed 5 days of use because of the potential for adverse reactions associated with prolonged therapy (>5 days). Single doses of ketorolac have been shown to be safe and effective in pediatric patients between the ages of 2 and 16 years however, there are limited data to support the use of multiple doses in pediatric patients. 

---